2020 Revenues ($USD) : $26,617,000,000
2020 R&D spend : $5,991,000,000
2020 Number of Employees : 76,100
Fiscal Year End : 12/31/2020
Key People : Pascal Soriot, CEO; Marc Dunoyer, CFO; Katarina Ageborg, EVP, sustainability and chief compliance officer, president of AstraZeneca AB Sweden; Pam Cheng, EVP, operations and information technology; Ruud Dobber, EVP, BioPharmaceuticals business unit; David Fredrickson, EVP, Oncology business unit; Menelas (Mene) Pangalos, EVP, BioPharmaceuticals R&D; Jeff Pott, EVP, human resources and general counsel; Iskra Reic, EVP, Europe and Canada; Leon Wang, EVP, international

AstraZeneca is a Cambridge, U.K.-based company that was launched into the global spotlight last year when its COVID-19 vaccine candidate was one of a number of vaccines that have been widely approved and administered so far to flatten the curve of the pandemic. The EU authorized the AstraZeneca vaccine on Jan. 29 this year, though it has yet to receive U.S. FDA authorization. The World Health Organization granted the vaccine emergency use listing on February 15. In addition to COVID-19 vaccines, the biopharmaceutical company’s R&D efforts focus on oncology, cardiovascular, renal, metabolism, respiratory, immunology and other therapies in its R&D efforts. AstraZeneca received 29 approvals of new medicines or life-cycle management indications in 2020 and announced plans to pick up Alexion Pharmaceuticals in an acquisition deal worth $39 billion. –DK